Surgical Science Q2 2023: Short-term challenges – unchanged long-term prospects - Redeye

Redeye updates its estimates following Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’. We judge that notable positives from the report include c30% y/y Industry/OEM sales growth and EBITDA/EBIT aligning with our expectations. Notable negatives include net sales coming in c5% below our expectations due to c8% lower-than-expected Educational Products sales. We finetune our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/938639/surgical-science-q2-2023-short-term-challenges-unchanged-long-term-prospects?utm_source=finwire&utm_medium=RSS